IAS
NTLA icon

Insigneo Advisory Services’s Intellia Therapeutics NTLA Stock Holding History

Insigneo Advisory Services’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$129K Hold
10,030
– – 0.01% 670
2025
Q4 		$90.2K Buy
+10,030
New +$138K 0.01% 680

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Insigneo Advisory Services's NTLA Position: Q1 2026 in Review

Insigneo Advisory Services held its Intellia Therapeutics (NTLA) position steady in Q1 2026 at 10,030 shares worth $129K. The position accounts for 0.01% of the portfolio, ranked #670.

Insigneo Advisory Services first reported a position in NTLA in Q4 2025 and has held it in 2 quarters since. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Insigneo Advisory Services held 10,030 shares of Intellia Therapeutics worth $129K as of Q1 2026.
  • Insigneo Advisory Services left its Intellia Therapeutics share count unchanged in Q1 2026.
  • Intellia Therapeutics made up 0.01% of Insigneo Advisory Services's portfolio in Q1 2026, its #670 holding.
  • Insigneo Advisory Services first reported a position in Intellia Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Insigneo Advisory Services's 13F filing for Q1 2026, filed 12 May 2026.